Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X. Han B, et al. Among authors: xiu q. J Thorac Oncol. 2011 Jun;6(6):1104-9. doi: 10.1097/JTO.0b013e3182166b6b. J Thorac Oncol. 2011. PMID: 21532504 Free article. Clinical Trial.
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Zhou C, et al. Among authors: xiu q. Ann Oncol. 2015 Sep;26(9):1877-1883. doi: 10.1093/annonc/mdv276. Epub 2015 Jul 3. Ann Oncol. 2015. PMID: 26141208 Free article. Clinical Trial.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Zhou C, et al. Among authors: xiu q. Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. Lancet Oncol. 2011. PMID: 21783417 Clinical Trial.
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu CP, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Chen G, et al. Among authors: xiu q. Ann Oncol. 2013 Jun;24(6):1615-22. doi: 10.1093/annonc/mdt012. Epub 2013 Mar 1. Ann Oncol. 2013. PMID: 23456778 Free article. Clinical Trial.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Ahn MJ, et al. Among authors: xiu q. Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23. Lung Cancer. 2012. PMID: 22534669 Clinical Trial.
Study of e^{+}e^{-}→γωJ/ψ and Observation of X(3872)→ωJ/ψ.
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Alekseev M, Amoroso A, An FF, An Q, Bai Y, Bakina O, Ferroli RB, Ban Y, Begzsuren K, Bennett JV, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chai J, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen YB, Cheng W, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dou ZL, Du SX, Fan JZ, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Fu Y, Gao Q, Gao XL, Gao Y, Gao Y, Gao YG, Gao Z, Garillon B, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han S, Hao XQ, Harris FA, He KL, Heinsius FH, Held T, Heng YK, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang JS, Huang XT, Huang XZ, Huesken N, Hussain T, Andersson WI, Imoehl W, Irshad M, Ji Q, Ji QP, Ji XB, Ji XL, Jiang HL, Jiang XS, Jiang XY, Jiao JB, Jiao Z, Jin DP, Jin S, Jin … See abstract for full author list ➔ Ablikim M, et al. Among authors: xiu ql. Phys Rev Lett. 2019 Jun 14;122(23):232002. doi: 10.1103/PhysRevLett.122.232002. Phys Rev Lett. 2019. PMID: 31298909 Free article.
Measurement of Proton Electromagnetic Form Factors in e^{+}e^{-}→pp[over ¯] in the Energy Region 2.00-3.08 GeV.
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Alekseev M, Amoroso A, An FF, An Q, Anita, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Begzsuren K, Bennett JV, Berger N, Bertani M, Bettoni D, Bianchi F, Biernat J, Bloms J, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chai J, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen J, Chen ML, Chen SJ, Chen XR, Chen YB, Cheng W, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Fritsch M, Fu CD, Fu Y, Gao Q, Gao Y, Gao Y, Gao YG, Garillon B, Garzia I, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu S, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han S, Han TZ, Hao XQ, Harris FA, He KL, Heinsius FH, Held T, Heng YK, Himmelreich M, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang JS, Huang LQ, Huang XT, Huesken N, Hussain T, Ikegami Andersson W, Imoehl W, Irshad M, Ji Q, Ji QP, Ji XB, Ji XL, Jiang HL, Jiang XS, Jia… See abstract for full author list ➔ Ablikim M, et al. Among authors: xiu ql. Phys Rev Lett. 2020 Jan 31;124(4):042001. doi: 10.1103/PhysRevLett.124.042001. Phys Rev Lett. 2020. PMID: 32058790
168 results